 NEW YORK, Dec. 02, 2022 GLOBE NEWSWIRE Kaplan Fox Kilsheimer LLP is continuing its investigation of claims on behalf of investors in Y-mAbs Therapeutics, Inc. Y-mAbs or the Company NASDAQ: YMAB securities. If you purchased Y-mAbs securities and would like to discuss our investigation, please contact us by emailing or by ... The post Y-mAbs Therapeutics, Inc. NASDAQ: YMAB Investor Update: Kaplan Fox Continues to Investigate Potential Secu... 